Jyong Biotech (NASDAQ:MENS) Trading 2.7% Higher – Here’s Why

Jyong Biotech Ltd. (NASDAQ:MENS)’s stock price rose 2.7% during trading on Thursday . The company traded as high as $2.33 and last traded at $2.30. Approximately 14,428 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 37,089 shares. The stock had previously closed at $2.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, August 19th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Jyong Biotech currently has an average rating of “Sell”.

Jyong Biotech Trading Up 2.7%

The business’s 50 day moving average is $2.15 and its 200 day moving average is $2.12.

Institutional Investors Weigh In On Jyong Biotech

Several hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new position in Jyong Biotech in the 3rd quarter valued at $67,000. Geode Capital Management LLC lifted its position in shares of Jyong Biotech by 19.6% during the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after purchasing an additional 10,538 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Jyong Biotech during the third quarter valued at $512,000. Man Group plc bought a new position in shares of Jyong Biotech in the fourth quarter worth about $56,000. Finally, Jane Street Group LLC purchased a new position in Jyong Biotech in the 4th quarter worth about $275,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.